A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Nicholas C TurnerMelinda L TelliHope S RugoAudrey MailliezJohannes EttlEva-Maria GrischkeLida A MinaJudith BalmañaPeter Andreas FaschingSara A HurvitzAndrew M WardleyColombe ChappeyAlison L HannahMark E Robsonnull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline BRCA mutation.